Business Description
VYNE Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92941V3087
Total Employee Number:
10Description
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 997.12 | |||||
Equity-to-Asset | 0.95 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -33.78 | |||||
Beneish M-Score | -2.68 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -55.3 | |||||
3-Year EBITDA Growth Rate | 59.8 | |||||
3-Year EPS without NRI Growth Rate | 84.4 | |||||
3-Year FCF Growth Rate | 56 | |||||
3-Year Book Growth Rate | -55.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 29.14 | |||||
9-Day RSI | 35.07 | |||||
14-Day RSI | 38.5 | |||||
3-1 Month Momentum % | 1.53 | |||||
6-1 Month Momentum % | 13.74 | |||||
12-1 Month Momentum % | -55.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 20.86 | |||||
Quick Ratio | 20.86 | |||||
Cash Ratio | 20.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -117.2 | |||||
Shareholder Yield % | 0.44 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -5367.62 | |||||
Net Margin % | -4726.21 | |||||
EBITDA Margin % | -5362.56 | |||||
FCF Margin % | -5670.48 | |||||
OCF Margin % | -5670.48 | |||||
ROE % | -64.05 | |||||
ROA % | -55.5 | |||||
ROIC % | -1806.72 | |||||
3-Year ROIIC % | -63.2 | |||||
ROC (Joel Greenblatt) % | -21264.4 | |||||
ROCE % | -72.74 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 52.46 | |||||
PB Ratio | 0.75 | |||||
Price-to-Tangible-Book | 0.75 | |||||
EV-to-EBIT | 0.86 | |||||
EV-to-EBITDA | 0.86 | |||||
EV-to-Revenue | -46.31 | |||||
EV-to-Forward-Revenue | 0.19 | |||||
EV-to-FCF | 0.82 | |||||
Price-to-GF-Value | 0.92 | |||||
| Price-to-Net-Current-Asset-Value | 0.76 | |||||
| Price-to-Net-Cash | 0.78 | |||||
Earnings Yield (Greenblatt) % | 116.28 | |||||
FCF Yield % | -138.42 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VYNE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
VYNE Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.454 | ||
| EPS (TTM) ($) | -24.5 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -0.22 | ||
| 3-Year Sortino Ratio | -0.31 | ||
| Volatility % | 99.4 | ||
| 14-Day RSI | 38.5 | ||
| 14-Day ATR ($) | 4.090587 | ||
| 20-Day SMA ($) | 35.49625 | ||
| 12-1 Month Momentum % | -55.6 | ||
| 52-Week Range ($) | 14.025 - 79.75 | ||
| Shares Outstanding (Mil) | 0.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
VYNE Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
VYNE Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 73 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | 25.45 (+4.58%) | ||
| 0.02:1 Stock Split | 2026-07-27 | 25.45 (+4.58%) | ||
| USD 20.121000 Cash Dividend | 2026-07-22 | 44.64 (+13.86%) | ||
| General meeting for 2026 | 2026-07-16 | 37.86 (+5.75%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 33.52 (+0.09%) | ||
| Annual report for 2025 | 2026-02-27 | 29.69 (+5.08%) | ||
| General meeting for 2025 | 2025-12-12 10:00 | 20.26 (-3.55%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 16.90 (+5.33%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 17.38 (+4.01%) |
Show
Entries
VYNE Therapeutics Inc Frequently Asked Questions
What is VYNE Therapeutics Inc(VYNE)'s stock price today?
The current price of VYNE is $27.86. The 52 week high of VYNE is $79.75 and 52 week low is $14.03.
When is next earnings date of VYNE Therapeutics Inc(VYNE)?
The next earnings date of VYNE Therapeutics Inc(VYNE) is 2026-11-06 Est..
Does VYNE Therapeutics Inc(VYNE) pay dividends? If so, how much?
VYNE Therapeutics Inc(VYNE) does not pay dividend.
Press Release
Articles on VYNE Therapeutics Inc
ORBIMED ADVISORS LLC Buys VYNE Therapeutics Inc (VYNE) -- Shares Look 27% Overvalued on GF Value
Aug 12, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers